Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: Variation by age, sex, geographic location and ethnicity

Bone

Volumn 94, Issue , 2017, Pages 50-55

  van der Velde, R Y ^a,b   Wyers, C E ^a,b   Teesselink, E ^c   Geusens, P P M M ^c,d   van den Bergh, J P W ^a,b,d   de Vries, F ^c   Cooper, C ^e,f,g   Harvey, N C ^e,f   van Staa, T P ^h,i  

^a VIECURI MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HASSELT UNIVERSITY   (Belgium)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anti osteoporosis drugs; AOD; Epidemiology; Fracture; Osteoporosis; Secular trends

Indexed keywords

ALENDRONIC ACID; ANTIOSTEOPOROSIS DRUG; BISPHOSPHONIC ACID DERIVATIVE; CHEMICALS AND DRUGS; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID; STRONTIUM RANELATE; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT;

AGE; AGED; ARTICLE; CONTROLLED STUDY; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; MALE; OBSERVATIONAL STUDY; OSTEOPOROSIS; PRESCRIPTION; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREND STUDY; UNITED KINGDOM; ETHNIC GROUP; GEOGRAPHY; ORAL DRUG ADMINISTRATION; SEXUAL CHARACTERISTICS; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; AGE FACTORS; BONE DENSITY CONSERVATION AGENTS; DRUG PRESCRIPTIONS; ETHNIC GROUPS; FEMALE; GEOGRAPHY; HUMANS; INCIDENCE; MALE; OSTEOPOROSIS; SEX CHARACTERISTICS; UNITED KINGDOM;

EID: 84992187980     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2016.10.013     Document Type: Article

References (46)

1. [1] National Osteoporosis Society, URL http://www.nos.uk Accessed the 14th of December, 2015.
2. [2] Hernlund, E., Svedbom, A., Ivergard, M., Compston, J., Cooper, C., Stenmark, J., McCloskey, E.V., Jönsson, B., Kanis, J.A., Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos. 8:136 (2013), 82–83.
3. [3] Johnell, O., Kanis, J.A., An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17:12 (2006 Dec), 1726–1733.
4. [4] British Orthopaedic Association, The Care of Patients With Fragility Fracture. 2007.
5. [5] Kanis, J.A., Johnell, O., De Laet, C., Johansson, H., Oden, A., Delmas, P., Eisman, J., Fujiwara, S., Garnero, P., Kroger, H., McCloskey, E.V., Mellstrom, D., Melton, L.J., Pols, H., Reeve, J., Silman, A., Tenenhouse, A., A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:2 (2004), 375–382.
6. [6] Sernbo, I., Johnell, O., Consequences of a hip fracture: a prospective study over 1 year. Osteoporos. Int. 3:3 (1993 May), 148–153.
7. [7] Burge, R.T., Worley, D., Johansen, A., et al. The cost of osteoporotic fractures in the UK: projections for. J. Med. Econ. 4 (2000–2020), 51–52.
8. [8] Ström, O., Borgström, F., Kanis, J., Compston, J., Cooper, C., McCloskey, E.V., Jönsson, B., Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos. 6 (2011), 59–155.
9. [9] Compston, J., Cooper, A., Cooper, C., Francis, R., Kanis, J.A., Marsh, D., McCloskey, E.V., Reid, D.M., Selby, P., Wilkins, M., National Osteoporosis Guideline Group (NOGG). Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:2 (2009 Feb 20), 105–108.
10. [10] Vaile, J., Sullivan, L., Bennet, C., Bleasel, J., First fracture project: addressing the osteoporosis care gap. Intern. Med. J. 37:10 (2007 Oct), 717–720.
11. [11] Nayak, S., Roberts, M.S., Greenspan, S.L., Factors associated with diagnosis and treatment of osteoporosis in older adults. Osteoporos. Int. 20:11 (2009 Nov), 1963–1976.
12. [12] Elliot-Gibson, V., Bogoch, E.R., Jamal, S.A., Beaton, D.E., Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systemic review. Osteoporos. Int. 15:10 (2004 Oct), 767–778.
13. [13] Giangregorio, L., Papaioannou, A., Cranney, A., Zytaruk, N., Adachi, J.D., Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin. Arthritis Rheum. 35:5 (2006;Apr), 293–305.
14. [14] Balasubramanian, A., Tosi, L., Lane, J., Dirschl, R., Ho, P.-R., O'Malley, C., Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J. Bone Joint Surg. Am., 96(7), 2014 Apr 2 e52.
15. [15] Watson, J., Wise, L., Green, J., Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur. J. Clin. Pharmacol. 63:9 (2007 Sep), 843–849.
16. [16] Klop, C., Gibson-Smith, D., Elders, P.J., Welsing, P.M., Leufkens, H.G., Harvey, N.C., Bijlsma, J.W., van Staa, T.-P., de Vries, F., Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010. Osteoporos. Int. 26:7 (2015 Jul), 1919–1928.
17. [17] Williams, T., van Staa, T.-P., Puri, S., Eaton, S., Recent advances in the utility and use of the general practice research database as an example of a UK primary care data resource. Ther. Adv. Drug Saf. 3:2 (2012 Apr), 89–99.
18. [18] Chisholm, J., The read clinical classification. BMJ, 300(6732), 1990 Apr 28, 1092.
19. [19] van Staa, T.-P., Wegman, S., de Vries, F., Leufkens, B., Cooper, C., Use of statins and risk of fractures. JAMA 285:14 (2001 Apr 11), 1850–1855.
20. [20] van Staa, T.-P., Abenhaim, L., Cooper, C., Zhang, B., Leufkens, H.G., The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol. Drug Saf. 9:5 (2000 Sep), 359–366.
21. [21] Khan, N.F., Harrison, S.E., Rose, P.W., Validity of diagnostic coding within the general practice research database: a systematic review. Br. J. Gen. Pract. 60:572 (2010 Mar), e128–e136.
22. [22] Herrett, E., Thomas, S.L., Smeeth, L., Validity of diagnoses in the general practice research database. Br. J. Gen. Pract. 61:588 (2011 Jul), 438–439.
23. [23] Herrett, E., Thomas, S.L., Schoonen, W.M., Smeeth, L., Hall, A.J., Validation and validity of diagnoses in the general practice research database: a systematic review. Br. J. Clin. Pharmacol. 69:1 (2010 Jan), 4–14.
24. [24] Mathur, R., Bhaskaran, K., Chaturvedi, N., Leon, D.A., vanStaa, T., Grundy, E., Smeeth, L., Completeness and usability of ethnicity data in UK-based primary care and hospital databases. J. Public Health (Oxf.) 36 (2014), 684–692.
25. [25] Jaglal, S.B., Weller, I., Mamdani, M., Hawker, G., Kreder, H., Jaakkimainen, L., Adachi, J.D., Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong?. J. Bone Miner. Res. 20:6 (2005 Jun), 898–905.
26. [26] Huot, L., Couris, C.M., Tainturier, V., Jaglal, S., Colin, C., Schott, A.M., Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study. Osteoporos. Int. 19:7 (2008 Jul), 1047–1054.
27. [27] Wang, L., Shawn Tracy, C., Moineddin, R., Upshur, R.E., Osteoporosis prescribing trends in primary care: a population-based retrospective cohort study. Prim. Health Care Res. Dev. 14:1 (2013 Jan), 1–6.
28. [28] van der Velde, R.Y., Wyers, C.E., Curtis, E.M., Geussens, P.P.M.M., van den Bergh, J.P.W., de Vries, F., Cooper, C., van Staa, T.P., Harvey, N.C., Secular trends in fracture incidence in the UK between. Osteoporos. Int., 1990 and 2012, 10.1007/s00198-016-3650-3.
29. [29] Devold, H.M., Doung, G.M., Tverdal, A., Furu, K., Meyer, H.E., Falch, J.A., Sogaard, A.J., Prescriptions of anti-osteoporosis drugs during 2004–2007-a nationwide register study in Norway. Eur. J. Clin. Pharmacol. 66:3 (2010 Mar), 299–306.
30. [30] National Institute for Health and Care Excellence, TA160 Osteoporosis-primary Prevention., 2008/2011 Available at https://www.nice.org.uk/guidance/ta160.
31. [31] National Institute for Health and Care Excellence, TA161 Osteoporosis-secondary Prevention., 2008/2011 Available at https://www.nice.org.uk/guidance/ta161.
32. [32] Feudjo-Tepie, M., Ferguson, S., Roddam, A., Taylor, A., Bayly, J., Critchlow, C., Comorbidities, bone- sparing agent prescription history and their determinations among postmenopausal women in UK primary care settings: a retrospective database study. Arch. Osteoporos., 10, 2015, 41.
33. [33] Jha, S., Wang, Z., Laucis, N., Bhattacharyya, T., Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: an ecological analysis. J. Bone Miner. Res. 30:12 (2015 Dec), 2179–2187.
34. [34] Peeters, G., Tett, S.E., Duncan, E.L., Mishra, G.D., Dobson, A.J., Osteoporosis medication dispensing for older Australian women from 2002 to 2010: influences of publications, guidelines, marketing activities and policy. Pharmacoepidemiol. Drug Saf. 23:12 (2014 Dec), 1303–1311.
35. [35] Wysowski, D.K., Greene, P., Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002–2012. Bone 57:2 (2013 Dec), 423–428.
36. [36] Shane, E., Burr, D., Abrahamsen, B., Adler, R.A., Brown, T.D., Cheung, A.M., Cosman, F., Curtis, J.R., Dell, R., Dempster, D.W., Ebeling, P.R., Einhorn, T.A., Genant, H.K., Geusens, P., Klaushofer, K., Lane, J.M., McKiernan, F., McKinney, R., Ng, A., Nieves, J., O'Keefe, R., Papapoulos, S., Howe, T.S., van der Meulen, M.C., Weinstein, R.S., Whyte, M.P., Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 29:1 (2014 Jan), 1–23.
37. [37] Kanis, J.A., Svedbom, A., Harvey, N., McCloskey, E.V., The osteoporosis treatment gap. J. Bone Miner. Res. 29:9 (2014 Sep), 1926–1928, 10.1002/jbmr.2301 PubMed PMID: 24956507.
38. [38] Curtis, E.M., van der Velde, R.Y., Moon, R.J., van den Bergh, J.P.W., Geusens, P.P.M.M., de Vries, F., van Staa, T.-P., Cooper, C., Harvey, N.C., Epidemiology of fractures in the United Kingdom 1988-2012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone 87 (2016 Jun), 19–26, 10.1016/j.bone.2016.03.006.
39. [39] ONS, UK Census. 2011.
40. [40] Liu, Z., Weaver, J., de Papp, A., Li, Z., Martin, J., Allen, K., Hui, S., Imel, E.A., Disparities in osteoporosis treatments. Osteoporos. Int. 27:2 (2016 Feb), 509–519.
41. [41] Cunningham, T.D., Di Pace, B.S., Ullal, J., Osteoporosis treatment disparities: a 6-year aggregate analysis from national survey data. Osteoporos. Int. 25:9 (2014 Sep), 2199–2208.
42. [42] Black, D.M., Cummings, S.R., Karpf, D.B., Cauley, J.A., Thompson, D.E., Nevitt, M.C., Bauer, D.C., Genant, H.K., Haskell, W.L., Marcus, R., Ott, S.M., Torner, J.C., Quandt, S.A., Reiss, T.F., Ensrud, K.E., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348 (1996), 1535–1541.
43. rd, Brown, J., Eriksen, E.F., Hoseyni, M.S., Axelrod, D.W., Miller, P.D., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 282:14 (1999 Oct), 1344–1352.
44. [44] Rossouw, J.E., Anderson, G.L., Prentice, R.L., LaCroix, A.Z., Kooperberg, C., Stefanick, M.L., Jackson, R.D., Beresford, S.A., Howard, B.V., Johnson, K.C., Kotchen, J.M., Ockene, J., Writing Group for the Women's Health Initiative Investigators, Risks and benefits of oestrogens plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:3 (2002 Jul), 321–333.
45. [45] Royal College of Physicians, Osteoporosis: Clinical Guidelines for Prevention and Treatment. 1999, RCP, London.
46. [46] Herrett, E., Gallagher, A.M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T.-P., Smeeth, L., Data resource profile: clinical practice research datalink (CPRD). Int. J. Epidemiol. 44:3 (2015 Jun), 827–836.